FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer

By A. Dilawari, M. Shah, G. Ison, H. Gittleman, M. Fiero, Ankit Shah, Salaheldin S Hamed, J. Qiu, Jingyu Yu, Wimolnut Manheng and 14 more. 2023

Subfields: Obstetrics and Gynecology, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “FOLR1 has likewise gained clinical relevance, as underscored by the FDA approval of mirvetuximab soravtansine-gynx, an antibody-drug conjugate for FRα-positive, platinum-resistant ovarian cancer [25].”